Overview

Pain Response to Cannabidiol in Opioid-induced Hyperalgesia, Acute Nociceptive Pain and Allodynia By Using a Model Mimicking Acute Pain in Healthy Adults

Status:
Completed

Trial end date:
2020-10-15

Target enrollment:

Participant gender:

Summary

Prospective, randomized, placebo-controlled, double-blinded, crossover study to investigate the effect of cannabidiol (CBD) on remifentanil-induced hyperalgesia in healthy volunteers in a well-established acute pain model. Participants are randomized according to the order of the two treatments (CBD + Remifentanil or Placebo + Remifentanil).

Phase:

N/A

Details

Lead Sponsor:

University Hospital, Basel, Switzerland

Treatments:

Epidiolex
Remifentanil